<DOC>
	<DOCNO>NCT00606346</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety clinical status pediatric patient Inflammatory Bowel Disease ( IBD ) . Particular attention direct record safety outcomes report association infliximab prescribe IBD therapy . In addition , information disease status quality life collect .</brief_summary>
	<brief_title>A Multicenter , Prospective , Long-term , Observational Registry Pediatric Patients With Inflammatory Bowel Disease</brief_title>
	<detailed_description>This registry study include volunteer pediatric patient : approximately 2,000 pediatric patient Crohn 's Disease treat infliximab approximately 2,000 pediatric patient Crohn 's Disease receive therapy infliximab . Approximately 1,000 pediatric patient Ulcerative Colitis Indeterminant Colitis also enrol . All patient treatment IBD decide treat physician consultation patient base usual clinical practice . Patient information collect time enrollment every 6 month approximately 20 year . Data collection include disease characteristic , IBD medication , safety assessment include adverse event . Patients also ask complete brief questionnaire describe school and/or work attendance order ass quality life . Some patient may ask participate substudy evaluate blood level formation protein may develop treatment infliximab . A small amount additional blood may take time routine blood draw part patient 's routine medical care determine treat physician . There three study part post marketing requirement IBD - C0168Z02 , REMICADEPIB4002 REMICADEPIB4003 . There one combine database protocol analysis perform use aggregate data . All report publication generate combined database . No study agent administer registry . All patient receive standard-of-care treatment prescribe patient 's physician .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>C0168Z02 Confirmed diagnosis Crohn 's disease , Ulcerative Colitis , Indeterminate Colitis least 2 month The parent/legal guardian must capable provide write informed consent , assent obtain child accord local regulation ( age assent give may vary IRB EC ) . The patient 's physician expect patient schedule medical encounter ( and/or direct contact ) least every 6 month , part usual care , time enrollment . REMICADEPIB4002 REMICADEPIB4003 : Confirmed diagnosis Crohn 's disease Ulcerative Colitis least 2 month C0168Z02 : 17 year age old , exception patient participate Sponsor 's conduct pediatric IBD clinical trial . Have Crohn'slike disease associate genetic disease ( eg , glycogen storage disease ) . The patient parent/guardian able adhere protocol requirement . Are participate clinical trial investigational agent commercially available . REMICADEPIB4002 REMICADEPIB4003 : Less 6 year age 17 year age old .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Indeterminate Colitis</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Immunomodulators</keyword>
	<keyword>infliximab</keyword>
	<keyword>TNF-alpha</keyword>
</DOC>